Harm

• Cue Biopharma announced positive results from a Phase 2 clinical trial of its CUE-221 treatment for chronic spontaneous urticaria, a condition causing chronic hives. • The trial results demonstrated that the drug achieved significant efficacy and maintained a favorable safety profile for patients. • These findings suggest a potential new therapeutic option for patients suffering from chronic hives who may not respond to existing treatments.

• The India Women's cricket team, led by Harmanpreet Kaur, is preparing for the 2026 Asian Games following their recent victory in the Women's Asia Cup. • India secured their eighth Asia Cup title on September 13 in Dubai by defeating Sri Lanka by 72 runs. • This momentum positions the team as a strong contender for the gold medal in the upcoming Asian Games.

• Connect Biopharma reported that its asthma trial reduced failures by 66% based on recent patient data. • Lung function improved by 250 mL by Day 7 compared to 120 mL for the placebo group among 160 patients. • These results impact the drug's regulatory approval and market potential because investors use FEV1, a measure of how much air a person can exhale, to judge if respiratory treatments work.

Exclusive: Screening if used alone risks leading people to believe they are inevitably going to develop dementiaFollow our Australia news live blog for latest updatesGet our breaking news email, free app or daily news podcastResearchers have warned that social media may be misleading healthy people into taking Alzheimer’s blood tests, causing severe anxiety over biological markers that may never actually cause dementia.Blood-based biomarker tests, including p-tau217 and p-tau181, detect biological signs of changes in the brain associated with Alzheimer’s disease, which is a progressive brain disorder and the leading cause of dementia. Continue reading...

• The White House signed secretive agreements with 26 drugmakers that may exempt various medicines from mandatory price reductions in Medicare. • A new analysis indicates these deals could drastically reduce the projected savings from the "most-favored nation" pricing policy, which aims to align U.S. drug costs with lower prices paid abroad. • These exemptions could limit the government's ability to lower prescription costs for millions of Medicare beneficiaries.

• Helus Pharma will participate in the Morgan Stanley Healthcare Conference, where Michael Halstead will give a fireside chat on September 16. • The chat will be webcast live at 8:30 a.m. EDT and a replay will be available on Helus Pharma's investor relations website. • The company's products, including HLP003 and HLP004, have not been evaluated by regulatory authorities such as the US Food and Drug Administration, and their efficacy has not been confirmed by approved research.

• The CEO of Helus Pharma will participate in a live webcast on September 14 during the H.C. Wainwright conference in New York. • The presentation begins at 9 a.m. EDT and will be available for replay on the company's Events & Presentations page. • Investors and partners can gain direct insight into the company's current status and its various programs, including HLP003 and HLP004.

• The Sensex dropped 383 points and the Nifty fell below 23,800 during the most recent trading session. • Pharma stocks rose 0.75%, while other sectors including Information Technology, Media, Metal, PSU Bank, and Realty fell between 1% and 2.8%. • Investors may treat price rebounds as opportunities to sell rather than a recovery until the Nifty reclaims the 23,900–24,000 zone.

• India defeated Pakistan by 7 wickets in the Women's Asia Cup 2026 league match, with Harmanpreet Kaur hitting a six to secure the win. • The victory concludes India's league campaign and maintains their dominant record over their rivals across batting, bowling, and fielding. • This result advances India to the knockout stage while forcing Pakistan to evaluate their performance before facing Hong Kong, China.

• Helus Pharma CEO Michael Halstead is scheduled to participate in a fireside chat during a conference on September 11. • The event will be webcast at 8 a.m. EDT, with a recording later made available on the company's investor relations website. • The presentation comes amid ongoing development of the company's NSA programs, including HLP003 and HLP004.

• 60 Degrees Pharmaceuticals will release a public presentation on September 11 regarding its medicines for vector-borne diseases. • Following the presentation, company management will meet with institutional investors in New York from September 14-16. • The company currently commercializes ARAKODA (tafenoquine) for malaria prevention in the U.S. and Australia and is conducting three active clinical trials for babesiosis.

• India secured a dominant 94-run victory over Thailand in their Group A Women's T20 Asia Cup opener on Sunday. • Shafali Verma led the scoring with an explosive 64 off 36 balls, helping India reach 159/9 despite a late batting collapse. • India's bowling attack dismantled Thailand, bowling them out for just 65 runs to seal the win.

• India secured a dominant 94-run victory over Thailand in their Women's Asia Cup 2026 opening match in Dubai. • Shafali Verma led the batting with a rapid fifty off 19 balls, while Nandni Sharma and Deepti Sharma each claimed three wickets. • Deepti Sharma reached a milestone of 171 WT20I wickets, surpassing Thipatcha Putthawong and becoming the third Indian woman to play 150 WT20Is.

• The FDA approved updated 2026-2027 COVID-19 vaccines targeting the XFG variant on August 27, with doses shipping immediately to pharmacies, hospitals, and clinics. • While the vaccines are now physically available across the country, federal eligibility guidance remains unsettled, leaving uncertainty regarding who qualifies for the shots. • This rollout is critical for maintaining immunity against evolving strains, though clarity on insurance coverage and specific recipient criteria is still missing.

Report shines light on ‘catastrophic situation’ where young people make themselves more ill to avoid losing supportSome of the most vulnerable children and young people in care are deliberately self-harming to avoid being abandoned when they get better or turn 18 and face a “cliff edge” of no further support, according to research.Abi Booth, a psychotherapist who works with children and young people, said some were in a “catastrophic situation” in which they were hurting themselves to keep their place in therapeutic facilities.In the UK, the youth suicide charity Papyrus can be contacted on 0800 068 4141 or email [email protected], and in the UK and Ireland Samaritans can be contacted on freephone 116 123. In the US, the 988 Suicide & Crisis Lifeline is at 988 or chat for support. In Australia, the crisis support service Lifeline is 13 11 14. Other international helplines can be found at befrienders.org Continue reading...

Former building commissioner David Chandler told inquiry of clashes with ‘loud and overbearing’ developer Jean NassifGet our breaking news email, free app or daily news podcastA fugitive Sydney developer allegedly warned the then-New South Wales building commissioner that he would “harm” him if he got in the way of his projects which were being inspected for defects, the corruption watchdog has heard.Giving evidence to the Independent Commission against Corruption on Thursday, David Chandler described an interaction he had with Toplace developments’ Jean Nassif. Continue reading...

Exclusive: Arturo Béjar, an ex-Facebook employee and whistleblower, said outcome ‘is not an all clear to say the product is safe’Meta agrees to major changes to Facebook and Instagram in settlementThe star witness in the US government’s landmark trial against Meta believes that a multibillion-dollar settlement reached on Wednesday does not go far enough to stop the social media giant’s harms to young users.“The limitations that are in the agreement are the equivalent of saying: ‘Well you can smoke as many cigarettes as you can in two hours a day,’” said whistleblower and ex-Facebook employee Arturo Béjar. “It doesn’t make the cigarettes any safer.” Continue reading...

Australian consumer watchdog says it received hundreds of complaints about the US-based dating site and its membershipsDating website eHarmony engaged in misleading and deceptive conduct over subscription traps that cost thousands of customers hundreds of dollars each, the federal court has found.The Australian Competition and Consumer Commission (ACCC) sued the US-based eHarmony in 2023 over claims of providing free dating on its platform, and the information consumers were given on subscription costs and renewal terms when buying a premium subscription. Continue reading...

Foundayo will be available on private prescription, with pharmacists warning of counterfeit GLP-1 problemA new daily pill that treats diabetes and helps with weight loss will be available in UK pharmacies from Monday.Pharmacists said the move would be welcome for people who cannot use weight-loss jabs, but also issued a warning over the growing problem of fake, unlicensed or counterfeit versions of GLP-1 tablets. Continue reading...

• Jubilant Pharmova Ltd announced that the USFDA has approved commercial batch manufacturing for the first product on Line 3, a new Isolator-based fill-and-finish line. • The approval applies to the Jubilant HollisterStier LLC (JHS) contract manufacturing facility located in Spokane, Washington, US. • This development is significant as it expands the production capabilities of Jubilant's subsidiary network, including Jubilant Pharma Holding Inc. and Jubilant Pharma Limited, Singapore.

Researchers at UCL warn repeated exam attempts may undermine confidence of students and raise risk of dropping outForcing teenagers who fail GCSEs into multiple resits has a negative impact on their mental health, according to research to be published as pupils receive their grades on Thursday.The study by academics at University College London (UCL) compared the mental wellbeing of students in England, Wales and Northern Ireland who failed to reach a grade 4 or equivalent in maths or English GCSEs – and found that only those in England, where resits are mandatory, showed significantly lower wellbeing. Continue reading...

• Helus Pharma has appointed Michael Halstead, the former President of Intra-Cellular Therapies, as its new Chief Executive Officer. • The company successfully completed patient enrollment for its Phase 3 APPROACH study evaluating the drug candidate HLP003. • To support late-stage development and future commercialization, Helus Pharma has secured $50 million in new funding.

• Researchers are testing a novel approach to treating depression by using anti-inflammatory drugs to calm the immune system rather than targeting brain chemicals. • Early results from a small clinical trial indicate that this immune-focused strategy shows promise in alleviating depressive symptoms. • Parallel developments in pharmacology include the emergence of a new drug designed to halt the progression of deadly fatty liver disease.

• The Medicines and Healthcare products Regulatory Agency (MHRA) is proposing a shake-up of the UK's medicines approval process to accelerate the development of treatments for rare diseases. • With approximately 10,000 rare diseases existing, the vast majority currently lack effective therapies, creating significant gaps in patient care. • The economic impact is severe, with the MHRA estimating that delayed diagnoses cost £340 million annually and health-related disability costs reach £4.7 billion.

• Helus Pharma reported its financial results for the first quarter of fiscal 2027, ending June 30, 2026, alongside key business updates. • The company appointed former Intra-Cellular Therapies President Michael Halstead as CEO to oversee late-stage development and future commercialization efforts. • Enrollment has been completed for the Phase 3 APPROACH pivotal study evaluating HLP003 for the treatment of Major Depressive Disorder (MDD).

• Helus Pharma has released its financial results for the first quarter of fiscal 2027 and shared recent business updates. • The company appointed Michael Halstead, the former President of Intra-Cellular Therapies, as its new Chief Executive Officer. • Halstead is tasked with guiding the company through the critical phases of late-stage development and eventual commercialization.

Study of 56m-year-old leaves counters claims from Trump administration members of ‘benefits’ of fossil fuel pollutionAdding huge quantities of carbon dioxide into the atmosphere is set to cause the Earth’s forests to wither and die rather than flourish, according to a new study that counters erroneous claims that fossil fuel pollution will green the planet.An analysis of fossilized leaf cells from a period known as the Paleocene-Eocene Thermal Maximum (or PETM), which occurred about 56 million years ago, has helped reconstruct how the world’s forests responded when planet-heating gases were previously being released at a rapid rate. Continue reading...